Dr. Pablo González obtained his Biochemist degree at the Pontifica Universidad Católica de Chile , along with his PhD in Molecular Genetics and Microbiology. He is currently a Young Investigator at the Millennium Institute on Immunology and Immunotherapy and Academic Chief Officer of this Center that harbors 100+ researchers. During his experimental training, he specialized in the field of immunology and more specifically in research areas that involve the interaction between harmful microbes and the host immune system. Because of the results obtained during his doctoral studies, he was awarded at his institution, by the Society of Cell Biology of Chile and received the Hermann Niemeyer medal awarded by the Society of Biochemistry and Molecular Biology of Chile. His experimental work has focused over the years on several bacteria, such as Salmonella and Mycobacteria (tuberculosis), as well as multiple viruses, such as the human respiratory syncytial virus, metapneumovirus and herpes simplex viruses. He performed a first post-doctorate training at the P. Universidad Católica de Chile and later at the Howard Hughes Medical Institute (HHMI) at the Albert Einstein College of Medicine, New York, USA. There, he trained on microbial genetics to genetically modify M. tuberculosis and herpes simplex viruses. Highlights of his research include the development of promising vaccine against herpes simplex viruses, which was recently published in the journal eLife and which should move on soon onto clinic settings, as well as studies on fundamental aspects of immunology, such as the effects of TCR ligand density on the activation of T cells and viral immune evasion. Some of his studies have been published in the journal Proceedings of the National Academy of Sciences of the United States of America and other high impact journals. Currently, his laboratory is working on immune evasion aspects of herpesviruses.